Literature DB >> 17445177

Preliminary analysis of a KIR haplotype estimation algorithm: a simulation study.

P A Gourraud1, K Gagne, J D Bignon, A Cambon-Thomsen, D Middleton.   

Abstract

The analysis of Killer cell immunoglobulin-like receptors (KIRs) in terms of haplotypes have only been done through genotyping numerous and selected families. Consequently and schematically, KIR haplotypes have been roughly described by two groups (A and B) based on their gene contents. No further KIR adapted methods have been applied to the estimation of haplotype frequencies using unrelated data. We propose here a maximum likelihood (ML) estimation of KIR haplotype frequencies. ML estimation was developed as an extension of those successfully applied to human leukocyte antigen (HLA) data including the handling of missing values and HLA nomenclature. It has been implemented using an adapted Expectation Masimisation algorithm. KIR types on 11 loci in more than 40 Irish families were used to validate the method in a simulation study. Estimated haplotype frequencies are compared to the phase known. Various allele or gene frequency estimation methods were also compared. We demonstrated the interest and reliability of the haplotype method and underline the effect of the sample size on the quality of the estimation. The ML haplotype method also provides by collapsing more accurate estimation of allele or gene frequencies in population. Such an algorithm opens new perspectives in the analysis of KIR genotypes. Large sample size studies are required using phase-known data and/or simulations. It would allow a genotype-based approach to explore the KIR gene haplotype diversity. The haplotype frequencies may be used to compare populations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17445177     DOI: 10.1111/j.1399-0039.2006.762_4.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  8 in total

1.  Analytical methods for immunogenetic population data.

Authors:  Steven J Mack; Pierre-Antoine Gourraud; Richard M Single; Glenys Thomson; Jill A Hollenbach
Journal:  Methods Mol Biol       Date:  2012

Review 2.  The immunogenetics of multiple sclerosis: A comprehensive review.

Authors:  Jill A Hollenbach; Jorge R Oksenberg
Journal:  J Autoimmun       Date:  2015-07-02       Impact factor: 7.094

3.  Refining the association of MHC with multiple sclerosis in African Americans.

Authors:  Joseph P McElroy; Bruce A C Cree; Stacy J Caillier; Peter K Gregersen; Joseph Herbert; Omar A Khan; Jan Freudenberg; Annette Lee; S Louis Bridges; Stephen L Hauser; Jorge R Oksenberg; Pierre-Antoine Gourraud
Journal:  Hum Mol Genet       Date:  2010-05-12       Impact factor: 6.150

4.  Linkage disequilibrium organization of the human KIR superlocus: implications for KIR data analyses.

Authors:  Pierre-Antoine Gourraud; Ashley Meenagh; Anne Cambon-Thomsen; Derek Middleton
Journal:  Immunogenetics       Date:  2010-09-29       Impact factor: 2.846

5.  Methods for assessing gene content diversity of KIR with examples from a global set of populations.

Authors:  Richard M Single; Maureen P Martin; Diogo Meyer; Xiaojiang Gao; Mary Carrington
Journal:  Immunogenetics       Date:  2008-09-17       Impact factor: 2.846

Review 6.  The immunogenetics of neurological disease.

Authors:  Maneesh K Misra; Vincent Damotte; Jill A Hollenbach
Journal:  Immunology       Date:  2017-12-11       Impact factor: 7.397

7.  Killer cell immunoglobulin-like receptor (KIR) gene content variation in the HGDP-CEPH populations.

Authors:  Jill A Hollenbach; Isobel Nocedal; Martha B Ladner; Richard M Single; Elizabeth A Trachtenberg
Journal:  Immunogenetics       Date:  2012-07-01       Impact factor: 2.846

8.  Estimating KIR Haplotype Frequencies on a Cohort of 10,000 Individuals: A Comprehensive Study on Population Variations, Typing Resolutions, and Reference Haplotypes.

Authors:  Cynthia Vierra-Green; David Roe; Jyothi Jayaraman; John Trowsdale; James Traherne; Rui Kuang; Stephen Spellman; Martin Maiers
Journal:  PLoS One       Date:  2016-10-10       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.